Actively Recruiting
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Led by Tianjin Medical University · Updated on 2025-02-11
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the usefulness of 68Ga/18F-Pentixafor/Pentixather PET/CT imaging for diagnosing primary and metastatic lesions in patients with various CXCR4-related diseases. The study aims to assess how well this imaging method detects disease sites by measuring lesion uptake and calculating diagnostic accuracy measures such as sensitivity, specificity, and predictive values. Participants receive a single intravenous injection of 2-5 mCi of the radiotracer 68Ga/18F-Pentixafor/Pentixather, followed by PET/CT imaging to visualize lesions. This procedure is used either for initial disease assessment or to detect recurrence. The imaging results are quantified using the maximum standardized uptake value (SUVmax). During the study, participants undergo PET/CT scans and have their lesion uptake measured. Researchers evaluate the standardized uptake value after 30 days, along with the diagnostic effectiveness of the imaging method. The study includes patients aged 18 to 80 years with suspected or confirmed untreated CXCR4-related diseases, and participation may include healthy volunteers. Safety and allergy monitoring are also part of the study process.
CONDITIONS
Brief Title
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspected or confirmed untreated lymphoproliferative and other CXCR4-related disease patients
- Had 18F-FDG PET/CT scan within the last two weeks
- Signed written informed consent
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Known allergy to Pentixafor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single intravenous injection of a radiotracer and undergo PET/CT imaging to assess CXCR4-related disease lesions.
1 visit (in-person)
Duration - 30 days
Participants are monitored for up to 30 days to evaluate diagnostic efficacy and standardized uptake values.
Follow-up visit(s) as needed within 30 days
Trial Site Locations
Total: 1 location
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
H
Haonan Yu, MD
S
Shaobo Yao, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here